SciSparc (NASDAQ:SPRC) versus Collegium Pharmaceutical (NASDAQ:COLL) Head to Head Contrast

SciSparc (NASDAQ:SPRC) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Insider & Institutional Ownership

25.1% of SciSparc shares are held by institutional investors. 1.5% of SciSparc shares are held by insiders. Comparatively, 2.5% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares SciSparc and Collegium Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
Collegium Pharmaceutical	5.13%	97.28%	13.87%

Earnings & Valuation

This table compares SciSparc and Collegium Pharmaceutical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$1.31 million	1.74	-$6.28 million	N/A	N/A
Collegium Pharmaceutical	$631.45 million	1.64	$69.19 million	$1.04	31.62

Collegium Pharmaceutical has higher revenue and earnings than SciSparc.

Volatility and Risk

SciSparc has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for SciSparc and Collegium Pharmaceutical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1	0	0	0	1.00
Collegium Pharmaceutical	0	2	1	2	3.00

Collegium Pharmaceutical has a consensus price target of $42.33, suggesting a potential upside of 28.75%. Given Collegium Pharmaceutical’s stronger consensus rating and higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than SciSparc.

Summary

Collegium Pharmaceutical beats SciSparc on 10 of the 13 factors compared between the two stocks.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.